Novavax (NVAX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.32
- EPS estimate
- −$0.38
- EPS surprise
- +15.75%
- Revenue surprise
- +7.97%
- Revenue
- $56.7M
- Revenue estimate
- $52.5M
- Reported
- Aug 6, 2026
Novavax reported Q2 2026 results on August 6, 2026. It posted a loss of $0.32 per share, narrower than the $0.38 loss analysts expected, a 15.75% beat. Revenue was $56.7 million against a $52.5 million estimate, about 8% higher. A year earlier, in Q2 2025, Novavax earned $0.62 per share on revenue of $239.2 million, so revenue fell about 76% year over year.
Results swing widely. Revenue ranged from $56.7 million in Q2 2026, the lowest here, to $734.6 million in Q3 2022. Novavax lost money in 14 of the last 20 quarters. Annual results improved each year: a loss of $8.40 per share in 2022, $5.53 in 2023 and $1.33 in 2024, then a profit of $2.41 in 2025. Q1 2025 was the strongest quarter in the table, at $2.93 per share on $666.7 million in revenue. The first half of 2026 shows a combined $0.38 loss, against a $3.55 profit a year earlier. Novavax beat EPS estimates in 11 of the 20 quarters.
Past Q3 reports came between November 5 and November 12, which points to early or mid-November 2026. The next report will show whether revenue recovers from the Q2 level.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 6, 2026 | −$0.38 | −$0.32 | +15.75% | $56.7M | SEC |
| Q1 2026 | May 6, 2026 | −$0.24 | −$0.06 | +75.19% | $139.5M | SEC |
| Q4 2025 | Feb 26, 2026 | −$0.48 | $0.11 | +122.69% | $147.1M | SEC |
| Q3 2025 | Nov 6, 2025 | −$1.20 | −$1.25 | −4.49% | $70.4M | SEC |
| Q2 2025 | Aug 6, 2025 | $0.01 | $0.62 | +7280.95% | $239.2M | SEC |
| Q1 2025 | May 8, 2025 | −$0.42 | $2.93 | +792.18% | $666.7M | SEC |
| Q4 2024 | Feb 27, 2025 | −$0.51 | −$0.51 | +0.78% | $88.3M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.79 | −$0.76 | +3.93% | $84.5M | SEC |
| Q2 2024 | Aug 8, 2024 | $1.67 | $0.99 | −40.72% | $415.5M | SEC |
| Q1 2024 | May 10, 2024 | −$1.06 | −$1.05 | +1.32% | $93.9M | SEC |
| Q4 2023 | Feb 28, 2024 | −$0.45 | −$1.44 | −221.43% | $291.3M | SEC |
| Q3 2023 | Nov 9, 2023 | −$2.22 | −$1.26 | +43.12% | $187.0M | SEC |
| Q2 2023 | Aug 8, 2023 | −$1.33 | $0.58 | +143.55% | $424.4M | SEC |
| Q1 2023 | May 9, 2023 | −$3.46 | −$3.41 | +1.50% | $81.0M | SEC |
| Q4 2022 | Feb 28, 2023 | −$1.01 | −$2.28 | −124.85% | $357.4M | SEC |
| Q3 2022 | Nov 8, 2022 | $1.57 | −$2.15 | −237.09% | $734.6M | — |
| Q2 2022 | Aug 9, 2022 | $3.64 | −$6.53 | −279.23% | $185.9M | — |
| Q1 2022 | May 10, 2022 | $2.69 | $2.56 | −4.77% | $704.0M | — |
| Q4 2021 | Mar 1, 2022 | −$1.80 | −$11.18 | −520.42% | $222.2M | — |
| Q3 2021 | Nov 5, 2021 | −$3.91 | −$4.31 | −10.31% | $178.8M | — |
Quarterly revenue
Frequently asked questions
When did Novavax (NVAX) last report earnings?
Novavax last reported on Aug 6, 2026, covering fiscal Q2 2026.
Did NVAX beat earnings estimates?
Yes. Novavax reported EPS of −$0.32 for Q2 2026 against a −$0.38 estimate — a 15.75% beat.
How much revenue did NVAX report last quarter?
Novavax reported $56.7M in revenue for Q2 2026, against a consensus estimate of $52.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.